We are live on ! Find out more

AirSculpt Technologies

AIRS

Market cap $187M

2.60 USD

-0.01

0.38%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

2.60

0.00

0%

1 day

-0.38%

5 days

-5.11%

1 month

-44.21%

3 months

-53.07%

6 months

52.05%

Year to date

40.54%

1 year

-60.96%

5 years

-83.64%

10 years

-83.64%

About: AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.

Employees: 363

Healthcare Medical Care Facilities

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 62.5%

Negative 12.5%

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AirSculpt Technologies, Inc. - AIRS

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AirSculpt Technologies, Inc. - AIRS

AirSculpt Sees Core Stabilization, Targets $100M-Plus GLP-1 Opportunity

AirSculpt Technologies NASDAQ: AIRS is seeing stabilization in its core body-contouring business after several quarters of declines, while expanding services aimed at patients using GLP-1 weight-loss drugs, Chief Executive Officer Yogi Jashnani said at a Canaccord consumer conference.

AirSculpt Sees Core Stabilization, Targets $100M-Plus GLP-1 Opportunity

AirSculpt Technologies, Inc. (AIRS) Q2 2026 Earnings Call Transcript

AirSculpt Technologies, Inc. (AIRS) Q2 2026 Earnings Call Transcript

AirSculpt Technologies, Inc. (AIRS) Q2 2026 Earnings Call Transcript

AirSculpt Technologies Q2 Earnings Call Highlights

AirSculpt Technologies NASDAQ: AIRS reported second-quarter revenue of $42.9 million, down 2.5% from the prior-year period, as the company cited stable revenue trends, positive same-center case growth and continued investment in marketing and expanded procedure offerings.

AirSculpt Technologies Q2 Earnings Call Highlights

Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday.

Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday's Pre-Market Session

AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results

MIAMI BEACH, Fla., Aug. 10, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the second quarter ended June 30, 2026.

AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results

AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for Second Quarter Fiscal 2026 Results

Company to Participate in Canaccord Genuity's 46th Annual Growth Conference Company to Participate in Canaccord Genuity's 46th Annual Growth Conference

AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for Second Quarter Fiscal 2026 Results

AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions

HONG KONG & SEOUL, South Korea--(BUSINESS WIRE)--AIRS Medical (“the Company”), a global leader in AI solutions for medical imaging, today announced a strategic growth investment from TA Associates (“TA”), a leading global private equity firm. The investment will help fuel AIRS Medical's next phase of global expansion, advancement of its AI-powered radiology technology solutions and ongoing product innovation. Founded in 2018, AIRS Medical develops AI-native magnetic resonance imaging (“MRI”) ac.

AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions

AirSculpt Technologies Announces Participation in Upcoming Investor Conferences

MIAMI BEACH, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS), an industry leader and provider of premium body contouring procedures, today announced that the Company will participate in upcoming investor conferences.

AirSculpt Technologies Announces Participation in Upcoming Investor Conferences

AirSculpt Technologies Sees Sales Rebound, GLP-1 Tailwind for Body Contouring Growth

AirSculpt Technologies NASDAQ: AIRS executives said the body contouring company has returned to same-store sales growth after more than two years of declines, while outlining plans to expand services tied to GLP-1 weight-loss drug side effects and eventually resume clinic growth across the U.S.

AirSculpt Technologies Sees Sales Rebound, GLP-1 Tailwind for Body Contouring Growth

See News Rankings

Price charts implemented using Lightweight Charts™